514 related articles for article (PubMed ID: 35912743)
1. The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey.
Caprioglio C; Garibotto V; Jessen F; Frölich L; Allali G; Assal F; Frisoni GB; Altomare D;
J Alzheimers Dis; 2022; 89(2):535-551. PubMed ID: 35912743
[TBL] [Abstract][Full Text] [Related]
2. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
[TBL] [Abstract][Full Text] [Related]
3. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
4. A biomarker study in long-lasting amnestic mild cognitive impairment.
Cerami C; Dodich A; Iannaccone S; Magnani G; Santangelo R; Presotto L; Marcone A; Gianolli L; Cappa SF; Perani D
Alzheimers Res Ther; 2018 Apr; 10(1):42. PubMed ID: 29695292
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker.
Massa F; Farotti L; Eusebi P; Capello E; Dottorini ME; Tranfaglia C; Bauckneht M; Morbelli S; Nobili F; Parnetti L
J Alzheimers Dis; 2019; 72(4):1193-1207. PubMed ID: 31683477
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
8. CSF p-tau/Aβ
Santangelo R; Masserini F; Agosta F; Sala A; Caminiti SP; Cecchetti G; Caso F; Martinelli V; Pinto P; Passerini G; Perani D; Magnani G; Filippi M
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3152-3164. PubMed ID: 32415550
[TBL] [Abstract][Full Text] [Related]
9. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
10. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting.
Jung NY; Kim ES; Kim HS; Jeon S; Lee MJ; Pak K; Lee JH; Lee YM; Lee K; Shin JH; Ko JK; Lee JM; Yoon JA; Hwang C; Choi KU; Lee EC; Seong JK; Huh GY; Kim DS; Kim EJ
J Alzheimers Dis; 2020; 74(2):473-490. PubMed ID: 32039853
[TBL] [Abstract][Full Text] [Related]
13. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
14. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
15. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
[TBL] [Abstract][Full Text] [Related]
16. Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements.
Nerattini M; Rubino F; Arnone A; Polito C; Mazzeo S; Lombardi G; Puccini G; Nacmias B; De Cristofaro MT; Sorbi S; Pupi A; Sciagrà R; Bessi V; Berti V
Neurol Sci; 2022 Apr; 43(4):2469-2480. PubMed ID: 34739618
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
18. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
Ramusino MC; Garibotto V; Bacchin R; Altomare D; Dodich A; Assal F; Mendes A; Costa A; Tinazzi M; Morbelli SD; Bauckneht M; Picco A; Dottorini ME; Tranfaglia C; Farotti L; Salvadori N; Moretti D; Savelli G; Tarallo A; Nobili F; Parapini M; Cavaliere C; Salvatore E; Salvatore M; Boccardi M; Frisoni GB
Eur J Nucl Med Mol Imaging; 2020 Feb; 47(2):270-280. PubMed ID: 31388720
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M; Chiotis K; Nordberg A;
Mol Psychiatry; 2021 Oct; 26(10):5888-5898. PubMed ID: 34593971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]